Ignite Creation Date:
2024-05-06 @ 1:21 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03992196
Status:
TERMINATED
Last Update Posted:
2023-10-30
First Post:
2019-06-17
Brief Title:
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Remote Open-Label Long-Term Follow-up Study to Determine the Safety Tolerability and Efficacy of Rotigotine Transdermal System as Monotherapy in Adolescents With Restless Legs Syndrome
Status:
TERMINATED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision Not a safety decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the long-term safety tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome RLS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None